Current Edition

Improving Screen Failure and Recruitment Rates in Alzheimer’s Disease Clinical Trials

Tomislav Babic, MD, PhD, and Henry J. Riordan, PhD,
respectively Vice President of Medical and Scientific Affairs/
Neuroscience Franchise and Executive Vice President
of Medical and Scientific Affairs and Global Lead for
Neuroscience at Worldwide Clinical Trials, explain how
appropriate study design and optimisation of recruitment/
screen fail rates are especially important as the field of
Alzheimer’s disease research moves toward the studies of
putative disease-modifying agents of AD and towards patients
that are very early in the disease spectrum; studies that have
notoriously high screen failure rates.…pdf